Krystal Biotech, Inc. (NASDAQ:KRYS) Accelerates Global Launches After Regulatory Wins
![]() |
Regulatory approvals and advancing clinical cohorts expand near-term commercial reach while technical momentum supports continued upside risk. Fundamental strength in margins and cash balances underpins the company’s current valuation profile. |








